Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: Results of the German Health Interview and Examination Survey (KiGGS)

BMJ Open

Volumn 2, Issue 6, 2012, Pages

  Knopf, Hildtraud ^a   Hölling, Heike ^a   Huss, Michael ^b   Schlack, Robert ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; FENCAMFAMIN; FENOZOLONE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; PEMOLINE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ALCOHOL CONSUMPTION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; GERMANY; HEALTH BEHAVIOR; HUMAN; IMMIGRATION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MATERNAL SMOKING; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; SCHOOL CHILD; SEX DIFFERENCE; SOCIAL STATUS;

EID: 84871051130     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000477     Document Type: Article

References (46)

1. MTA-Cooperative-Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004;113:762-9.
2. Deutsche Gesellschaft, für Kinder- und Jugendpsychiatrie, Psychotherapie. u. Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. In 3. überarbeitete Auflage edn.: Deutscher Ärzte Verlag, 2007:239-54.
3. Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003;111:97-109. (Pubitemid 36071038)
4. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev 2007;17:61-72. (Pubitemid 46355006)
5. Cormier E. Attention deficit/hyperactivity disorder: a review and update. J Pediatr Nurs 2008;23:345-57.
6. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006;163:579-85. (Pubitemid 44464565)
7. Vinker S, Vinker R, Elhayany A. Prevalence of methylphenidate use among Israeli children: 1998-2004. Clin Drug Invest 2006;26:161-7.
8. Hugtenburg JG, Heerdink ER, Egberts AC. Increased psychotropic drug consumption by children in the Netherlands during 1995-2001 is caused by increased use of methylphenidate by boys. Eur J Clin Pharmacol 2004;60:377-9. (Pubitemid 39062326)
9. Schmidt-Troschke SO, Ostermann T, Melcher D, et al. (The use of methylphenidate in children: analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions). Gesundheitswesen 2004;66:387-92. (Pubitemid 38886417)
10. Lohse M J, Müller-Oerlinghausen B. Psychopharmaka. In: Arzneiverordnungsreport 2009 Aktuelle Daten, Kosten Trends und Kommentare edn. Schwabe U, Paffrath D.eds. Heidelberg: Springer Medizin Verlag, 2009:767-810.
11. Glaeske G, Janhsen K. GEK-Arzneimittel-Report 2007. Auswertungsergebnisse der GEK-Arzneimitteldaten aus den Jahren 2005-2006. GEK Edition Schriftenreihe zur Gesundheitsanalyse, Band 55, 2007.
12. Bessou H, Zeeb H, Puteanus U. (Methylphenidate prescriptions in the city of Cologne: overrepresentation of privately insured patients. Results of an analysis based on prescription data). Gesundheitswesen 2007; 69:292-6. (Pubitemid 47047595)
13. Atzori P, Usala T, Carucci S, et al. Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol 2009;19:673-81.
14. Hugtenburg JG, Witte I, Heerdink ER. Determinants of compliance with methylphenidate therapy in children. Acta Paediatr 2006;95:1674-6. (Pubitemid 44863826)
15. Lindblad F, Hjern A. ADHD after fetal exposure to maternal smoking. Nicotine Tobacco Res: Off J Soc Res Nicotine Tobacco 2010;12:408-15.
16. Milberger S, Biederman J, Faraone SV, et al. Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? Am J Psychiatry 1996;153:1138-42. (Pubitemid 26299831)
17. Banerjee TD, Middleton F, Faraone SV. Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr 2007;96:1269-74. (Pubitemid 47300704)
18. Knopik VS, Heath AC, Jacob T, et al. Maternal alcohol use disorder and offspring ADHD: disentangling genetic and environmental effects using a children-of-twins design. Psychol Med 2006;36:1461-71. (Pubitemid 44355981)
19. Olfson M, Gameroff MJ, Marcus SC, et al. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2003;160:1071-7. (Pubitemid 41070965)
20. Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics 2007;119(Suppl 1):S99-106.
21. Foster BA, Read D, Bethell C. An analysis of the association between parental acculturation and children's medication use. Pediatrics 2009;124:1152-61.
22. Kurth BM, Kamtsiuris P, Holling H, et al. The challenge of comprehensively mapping children's health in a nation-wide health survey: design of the German KiGGS-Study. BMC Public Health 2008;8:196.
23. Kamtsiuris P, Lange M, Schaffrath Rosario A. (The German Health Interview and Examination Survey for Children and Adolescents (KiGGS): sample design, response and nonresponse analysis). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007;50:547-56.
24. Winkler J, Stolzenberg H. (Social class index in the Federal Health Survey). Gesundheitswesen 1999, 61 Spec No:S178-83.
25. Lange M, Kamtsiuris P, Lange C, et al. Sociodemographic characteristics in the German Health Interview and Examination Survey for Children and Adolescents (KiGGS) - operationalization and public health significance, taking as an example the assessment of the general status of health. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2007;50:578-99.
26. Schenk L, Ellert U, Neuhauser H. Children and adolescents in Germany with a migration background. Methodical aspects in the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007;50:590-9.
27. Schlack R, Holling H, Kurth BM, et al. The prevalence of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany. Initial results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007;50:827-35.
28. Kamtsiuris P, Bergmann E, Rattay P, et al. Use of medical services. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007;50:836-50.
29. Knopf H. Medicine use in children and adolescents. Data collection and first results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007;50:863-70.
30. Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Attention Disord 2007;10:335-42.
31. Preen DB, Calver J, Sanfilippo FM, et al. Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed. Austr N Z J Public Health 2007;31:120-6. (Pubitemid 46629499)
32. Sawyer MG, Rey JM, Graetz BW, et al. Use of medication by young people with attention-deficit/hyperactivity disorder. Med J Austr 2002;177:21-5. (Pubitemid 34763855)
33. Hjern A, Weitoft GR, Lindblad F. Social adversity predicts ADHD-medication in school children - a national cohort study. Acta Paediatr 2010;99:920-4.
34. Lindblad F, Weitoft GR, Hjern A. ADHD in international adoptees: a national cohort study. Eur Child Adolesc Psychiatry 2010;19:37-44.
35. Schirm E, Tobi H, Zito JM, et al. Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001;108:E25.
36. Acquaviva E, Legleye S, Auleley GR, et al. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry 2009;9:72.
37. Schubert I, Koster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Deutsches Arzteblatt Int 2010;107:615-21.
38. Zito JM, Safer DJ, de Jong-van den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Mental Health 2008;2:26.
39. Scheffler RM, Hinshaw SP, Modrek S, et al. The global market for ADHD medications. Health Affairs 2007;26:450-7.
40. Froehlich TE, Lanphear BP, Epstein JN, et al. Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 2007;161:857-64. (Pubitemid 47360887)
41. Miller AR, Lalonde CE, McGrail KM, et al. Prescription of methylphenidate to children and youth, 1990-1996. CMAJ 2001;165:1489-94. (Pubitemid 34060191)
42. Wittkampf LC, Smeets HM, Knol MJ, et al. Differences in psychotropic drug prescriptions among ethnic groups in the Netherlands. Soc Psychiatry Psychiatric Epidemiol 2010;45:819-26.
43. Thorell LB, Dahlstrom K. Children's self-reports on perceived effects on taking stimulant medication for ADHD. J Attention Disord 2009;12:460-8.
44. Derks EM, Hudziak JJ, Boomsma DI. Why more boys than girls with ADHD receive treatment: a study of Dutch twins. Twin Res Hum Genet: Off J Int Soc Twin Stud 2007;10:765-70. (Pubitemid 47608011)
45. Perwien A, Hall J, Swensen A, et al. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J Managed Care Pharm: JMCP 2004;10:122-9.
46. Knopf H, Du Y. Perceived adverse drug reactions among non-institutionalized children and adolescents in Germany. Br J Clin Pharmacol 2010;70:409-17.